Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics of Single Dose and 7-day Repeat Doses of PA9159 Nasal Spray in Healthy Chinese Adult
Conditions
Interventions
PA9159 nasal spray solution, 10 μg one day treatment
PA9159 nasal spray solution, 20 μg one day treatment
+5 more
Locations
1
China
Beijing TongRen Hospital
Beijing, Beijing Municipality, China
Start Date
November 10, 2021
Primary Completion Date
January 5, 2022
Completion Date
January 5, 2022
Last Updated
January 19, 2022
NCT07419230
NCT06732414
NCT05494346
NCT07110311
NCT04815668
NCT06846385
Lead Sponsor
Anhui Palo Alto Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions